FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2048522842> ?p ?o ?g. }

• W2048522842 endingPage "32" @default.
• W2048522842 startingPage "26" @default.
• W2048522842 abstract "Background Recent studies have shown that both steroids and angiotensin-converting enzyme (ACE) inhibitors improve kidney survival and decrease proteinuria in patients with immunoglobulin A nephropathy. In this study, we aim to investigate whether the addition of steroids to ACE-inhibitor therapy produces a more potent antiproteinuric effect and better protection of kidney function than an ACE inhibitor alone. Study Design Randomized controlled trial. Setting & Participants Patients with biopsy-proven immunoglobulin A nephropathy with proteinuria of 1 to 5 g/d of protein. Intervention 63 patients were randomly assigned to either cilazapril alone (ACE-inhibitor group; n = 30) or steroid plus cilazapril (combination group; n = 33). Outcomes & Measurements The primary end point was kidney survival, defined as a 50% increase in baseline serum creatinine level. Results After follow-up for up to 48 months, 7 patients in the ACE-inhibitor group (24.1%) reached the primary end point compared with 1 patient (3%) in the combination group. Kaplan-Meier kidney survival was significantly better in the combination group than the ACE-inhibitor group after 24 and 36 months (96.6% versus 75.7%, 96.6% versus 66.2%; P = 0.001). Urine protein excretion significantly decreased in patients in the combination group compared with the ACE-inhibitor group (time-average proteinuria, 1.04 ± 0.54 versus 1.57 ± 0.86 g/d of protein; P = 0.01). Multivariate analysis showed that combination treatment (hazard ratio, 0.1; 95% confidence interval, 0.014 to 0.946) and time-average proteinuria (hazard ratio, 14.3; 95% confidence interval, 2.86 to 71.92) were independent predictors of kidney survival. Limitations Small sample size, a single center, and slight imbalances at baseline. Conclusions Our results suggest that the addition of steroid to ACE-inhibitor therapy provided additional benefit compared with an ACE inhibitor alone. However, this was a pilot study with a small number of participants achieving the end points, and thus further validation is necessary. Recent studies have shown that both steroids and angiotensin-converting enzyme (ACE) inhibitors improve kidney survival and decrease proteinuria in patients with immunoglobulin A nephropathy. In this study, we aim to investigate whether the addition of steroids to ACE-inhibitor therapy produces a more potent antiproteinuric effect and better protection of kidney function than an ACE inhibitor alone. Randomized controlled trial. Patients with biopsy-proven immunoglobulin A nephropathy with proteinuria of 1 to 5 g/d of protein. 63 patients were randomly assigned to either cilazapril alone (ACE-inhibitor group; n = 30) or steroid plus cilazapril (combination group; n = 33). The primary end point was kidney survival, defined as a 50% increase in baseline serum creatinine level. After follow-up for up to 48 months, 7 patients in the ACE-inhibitor group (24.1%) reached the primary end point compared with 1 patient (3%) in the combination group. Kaplan-Meier kidney survival was significantly better in the combination group than the ACE-inhibitor group after 24 and 36 months (96.6% versus 75.7%, 96.6% versus 66.2%; P = 0.001). Urine protein excretion significantly decreased in patients in the combination group compared with the ACE-inhibitor group (time-average proteinuria, 1.04 ± 0.54 versus 1.57 ± 0.86 g/d of protein; P = 0.01). Multivariate analysis showed that combination treatment (hazard ratio, 0.1; 95% confidence interval, 0.014 to 0.946) and time-average proteinuria (hazard ratio, 14.3; 95% confidence interval, 2.86 to 71.92) were independent predictors of kidney survival. Small sample size, a single center, and slight imbalances at baseline. Our results suggest that the addition of steroid to ACE-inhibitor therapy provided additional benefit compared with an ACE inhibitor alone. However, this was a pilot study with a small number of participants achieving the end points, and thus further validation is necessary." @default.
• W2048522842 created "2016-06-24" @default.
• W2048522842 creator A5005960241 @default.
• W2048522842 creator A5022728200 @default.
• W2048522842 creator A5041259291 @default.
• W2048522842 creator A5062830831 @default.
• W2048522842 creator A5069849278 @default.
• W2048522842 creator A5074414128 @default.
• W2048522842 creator A5085971155 @default.
• W2048522842 date "2009-01-01" @default.
• W2048522842 modified "2023-10-09" @default.
• W2048522842 title "Combination Therapy of Prednisone and ACE Inhibitor Versus ACE-Inhibitor Therapy Alone in Patients With IgA Nephropathy: A Randomized Controlled Trial" @default.
• W2048522842 cites W1971106944 @default.
• W2048522842 cites W2047390341 @default.
• W2048522842 cites W2054418276 @default.
• W2048522842 cites W2063210769 @default.
• W2048522842 cites W2071111569 @default.
• W2048522842 cites W2089876742 @default.
• W2048522842 cites W2092224235 @default.
• W2048522842 cites W2101763206 @default.
• W2048522842 cites W2105803357 @default.
• W2048522842 cites W2107050894 @default.
• W2048522842 cites W2116730178 @default.
• W2048522842 cites W2117747806 @default.
• W2048522842 cites W2121362822 @default.
• W2048522842 cites W2123917517 @default.
• W2048522842 cites W2125136564 @default.
• W2048522842 cites W2136982243 @default.
• W2048522842 cites W2138670606 @default.
• W2048522842 cites W2139030893 @default.
• W2048522842 cites W2143144750 @default.
• W2048522842 cites W2145732657 @default.
• W2048522842 cites W2150318937 @default.
• W2048522842 cites W2157734027 @default.
• W2048522842 cites W2312400976 @default.
• W2048522842 cites W3156148333 @default.
• W2048522842 cites W4239867451 @default.
• W2048522842 doi "https://doi.org/10.1053/j.ajkd.2008.07.029" @default.
• W2048522842 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18930568" @default.
• W2048522842 hasPublicationYear "2009" @default.
• W2048522842 type Work @default.
• W2048522842 sameAs 2048522842 @default.
• W2048522842 citedByCount "185" @default.
• W2048522842 countsByYear W20485228422012 @default.
• W2048522842 countsByYear W20485228422013 @default.
• W2048522842 countsByYear W20485228422014 @default.
• W2048522842 countsByYear W20485228422015 @default.
• W2048522842 countsByYear W20485228422016 @default.
• W2048522842 countsByYear W20485228422017 @default.
• W2048522842 countsByYear W20485228422018 @default.
• W2048522842 countsByYear W20485228422019 @default.
• W2048522842 countsByYear W20485228422020 @default.
• W2048522842 countsByYear W20485228422021 @default.
• W2048522842 countsByYear W20485228422022 @default.
• W2048522842 countsByYear W20485228422023 @default.
• W2048522842 crossrefType "journal-article" @default.
• W2048522842 hasAuthorship W2048522842A5005960241 @default.
• W2048522842 hasAuthorship W2048522842A5022728200 @default.
• W2048522842 hasAuthorship W2048522842A5041259291 @default.
• W2048522842 hasAuthorship W2048522842A5062830831 @default.
• W2048522842 hasAuthorship W2048522842A5069849278 @default.
• W2048522842 hasAuthorship W2048522842A5074414128 @default.
• W2048522842 hasAuthorship W2048522842A5085971155 @default.
• W2048522842 hasConcept C126322002 @default.
• W2048522842 hasConcept C126894567 @default.
• W2048522842 hasConcept C134018914 @default.
• W2048522842 hasConcept C159641895 @default.
• W2048522842 hasConcept C168563851 @default.
• W2048522842 hasConcept C207103383 @default.
• W2048522842 hasConcept C27016395 @default.
• W2048522842 hasConcept C2779561371 @default.
• W2048522842 hasConcept C2779611605 @default.
• W2048522842 hasConcept C2780091579 @default.
• W2048522842 hasConcept C2780306776 @default.
• W2048522842 hasConcept C2781184683 @default.
• W2048522842 hasConcept C44249647 @default.
• W2048522842 hasConcept C555293320 @default.
• W2048522842 hasConcept C71924100 @default.
• W2048522842 hasConcept C84393581 @default.
• W2048522842 hasConcept C90924648 @default.
• W2048522842 hasConceptScore W2048522842C126322002 @default.
• W2048522842 hasConceptScore W2048522842C126894567 @default.
• W2048522842 hasConceptScore W2048522842C134018914 @default.
• W2048522842 hasConceptScore W2048522842C159641895 @default.
• W2048522842 hasConceptScore W2048522842C168563851 @default.
• W2048522842 hasConceptScore W2048522842C207103383 @default.
• W2048522842 hasConceptScore W2048522842C27016395 @default.
• W2048522842 hasConceptScore W2048522842C2779561371 @default.
• W2048522842 hasConceptScore W2048522842C2779611605 @default.
• W2048522842 hasConceptScore W2048522842C2780091579 @default.
• W2048522842 hasConceptScore W2048522842C2780306776 @default.
• W2048522842 hasConceptScore W2048522842C2781184683 @default.
• W2048522842 hasConceptScore W2048522842C44249647 @default.
• W2048522842 hasConceptScore W2048522842C555293320 @default.
• W2048522842 hasConceptScore W2048522842C71924100 @default.
• W2048522842 hasConceptScore W2048522842C84393581 @default.
• W2048522842 hasConceptScore W2048522842C90924648 @default.
• W2048522842 hasIssue "1" @default.

• next